Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results

202340 citationsJournal Articlehybrid Open Access

Authors

Proprietary or commercial disclosure may be found after the references.

Good health and well-being

Published in: Ophthalmology

Volume 130, Issue 7, pp. 735-747

Field-Weighted Citation Impact: 11.34